Paraoxonase-1 is a major determinant of clopidogrel efficacy

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470

Cytochrome P-450: Structure, Mechanism, and Biochemistry

de Montellano, O., & Paul, R. (1986) · Medical Entomology and Zoology · Cited by 2,663

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)

WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218

Genetic Determinants of Response to Clopidogrel and Cardiovascular Events

Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,728

Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy

Shuldiner, A. R. (2009) · JAMA · doi:10.1001/jama.2009.1232 · Cited by 1,505

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee

King, S. B., Smith, S. C., Hirshfeld, J. W., Jacobs, A. K., Morrison, D. A., Williams, D. O., 2005 WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.188208 · Cited by 1,014

Cytochrome P450

(2005) · Springer eBooks · doi:10.1007/b139087 · Cited by 840

Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite

Kazui, M., Nishiya, Y., Ishizuka, T., Hagihara, K., Farid, N. A., Okazaki, O., Ikeda, T., & Kurihara, A. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029132 · Cited by 835

Variability in platelet responsiveness to clopidogrel among 544 individuals

Serebruany, V. L., Steinhubl, S. R., Berger, P. B., Malinin, A. I., Bhatt, D. L., & Topol, E. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.09.067 · Cited by 777

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

BRANDT, J. T., CLOSE, S. L., ITURRIA, S. J., PAYNE, C. D., FARID, N. A., ERNEST, C. S., LACHNO, D. R., SALAZAR, D., & WINTERS, K. J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02775.x · Cited by 734

Analysis of Case-Cohort Designs

Barlow, W. E., Ichikawa, L., Rosner, D., & Izumi, S. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00102-x · Cited by 682

Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis

Sibbing, D., Braun, S., Morath, T., Mehilli, J., Vogt, W., Schömig, A., Kastrati, A., & von Beckerath, N. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.030 · Cited by 651

Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes

Harel, M., Aharoni, A., Gaidukov, L., Brumshtein, B., Khersonsky, O., Meged, R., Dvir, H., Ravelli, R. B. G., McCarthy, A., Toker, L., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb767 · Cited by 646

Relationship of Paraoxonase 1 (PON1) Gene Polymorphisms and Functional Activity With Systemic Oxidative Stress and Cardiovascular Risk

Bhattacharyya, T. (2008) · JAMA · doi:10.1001/jama.299.11.1265 · Cited by 533

Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes.

Adkins, S., Gan, K., Mody, M., & Du, B. N. L. (1993) · PubMed · Cited by 478

Platelet Function Monitoring in Patients With Coronary Artery Disease

Gurbel, P. A., Becker, R. C., Mann, K. G., Steinhubl, S. R., & Michelson, A. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.051 · Cited by 478

Structure and Stereochemistry of the Active Metabolite of Clopidogrel

Pereillo, J.-M., Maftouh, M., Andrieu, A., Uzabiaga, M.-F., Fedeli, O., Savi, P., Pascal, M., Herbert, J.-M., Maffrand, J.-P., & Picard, C. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1288 · Cited by 460

Human Serum Paraoxonase (pon1) Isozymes Q and R Hydrolyze Lactones and Cyclic Carbonate Esters

Billecke, S., Draganov, D., Counsell, R., Stetson, P., Watson, C., Hsu, C., & Du, B. N. L. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15082-9 · Cited by 402

Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration

Hulot, J.-S., Collet, J.-P., Silvain, J., Pena, A., Bellemain-Appaix, A., Barthélémy, O., Cayla, G., Beygui, F., & Montalescot, G. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.071 · Cited by 383

The Metabolism of Clopidogrel Is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by Atorvastatin

Clarke, T. A., & Waskell, L. A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.1.53 · Cited by 374

ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”

Holmes, D. R., Dehmer, G. J., Kaul, S., Leifer, D., O’Gara, P. T., & Stein, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.013 · Cited by 354

Four paraoxonase gene polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies

Wheeler, J. G., Keavney, B. D., Watkins, H., Collins, R., & Danesh, J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15642-0 · Cited by 317

Inhibition of Cytochrome P450 Enzymes

Correia, M. A., & Hollenberg, P. F. (2015) · Cytochrome P450 · doi:10.1007/978-3-319-12108-6_5 · Cited by 257

Pharmacokinetics of clopidogrel after administration of a high loading dose

Kastrati, A., Harlfinger, S., Gorchakova, O., Lazar, A., von Beckerath, N., Schömig, A., Schömig, E., & Taubert, D. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-02-0105 · Cited by 240

Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel

Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Ramírez, C., Cavallari, U., Trabetti, E., Sabaté, M., Hernández, R., Moreno, R., Escaned, J., et al. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000223867.25324.1a · Cited by 228

ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association

Writing Committee Members, Holmes, D. R., Dehmer, G. J., Kaul, S., Leifer, D., O'Gara, P. T., & Stein, C. M. (2010) · Circulation · doi:10.1161/cir.0b013e3181ee08ed · Cited by 223

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

Suh, J.-W. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.060664 · Cited by 204

Clopidogrel non-responsiveness and risk of cardiovascular morbidity: An updated meta-analysis

Marcucci, R., Gori, A. M., Giusti, B., Abbate, R., Gensini, G. F., & Sofi, F. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-06-0418 · Cited by 200

Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel

Bouman, H. J., PARLAK, E., van Werkum, J. W., Breet, N. J., Cate, H. T., Hackeng, C. M., ten Berg, J. M., & Taubert, D. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03733.x · Cited by 115

Metabolic Oxidative Cleavage of Thioesters: Evidence for the Formation of Sulfenic Acid Intermediates in the Bioactivation of the Antithrombotic Prodrugs Ticlopidine and Clopidogrel

Dansette, P. M., Libraire, J., Bertho, G., & Mansuy, D. (2009) · Chemical Research in Toxicology · doi:10.1021/tx8004828 · Cited by 97

Paraoxonase 1 protects against protein N ‐homocysteinylation in humans

Perła‐Kaján, J., & Jakubowski, H. (2009) · The FASEB Journal · doi:10.1096/fj.09-144410 · Cited by 91

On the Design of Synthetic Case-Control Studies

Prentice, R. L. (1986) · Biometrics · doi:10.2307/2531051 · Cited by 90

Determinants of variation in human serum paraoxonase activity

Rainwater, D. L., Rutherford, S., Dyer, T. D., Rainwater, E., Cole, S. A., VandeBerg, J. L., Almasy, L. A., Blangero, J., MacCluer, J. W., & Mahaney, M. C. (2008) · Heredity · doi:10.1038/hdy.2008.110 · Cited by 87

Recent developments in clopidogrel pharmacology and their relation to clinical outcomes

Gurbel, P. A., Antonino, M. J., & Tantry, U. S. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903107772 · Cited by 84

Platelet Adenosine Diphosphate P2Y12 Receptor Antagonism: Benefits and Limitations of Current Treatment Strategies and Future Directions

Angiolillo, D. J., & Ferreiro, J. L. (2010) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(10)70010-4 · Cited by 75

Inhibición del receptor plaquetario P2Y12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras

Angiolillo, D. J., & Ferreiro, J. L. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70010-5 · Cited by 68

Genetic Polymorphism ofCYP2C19Gene in the Stanislas Cohort. A link with Inflammation

Thiebault, C., Berrahmoune, H., Thompson, A., Bastien, B., Droesch, S., Siest, G., Foernzler, D., & Visvikis‐Siest, S. (2008) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2007.00417.x · Cited by 42

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

Scott, S. A., Sangkuhl, K., Stein, C. M., Hulot, J.-S., Mega, J. L., Roden, D. M., Klein, T. E., Sabatine, M. S., Johnson, J. A., & Shuldiner, A. R. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.105 · Cited by 962

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events: A Systematic Review and Meta-analysis

Holmes, M. V., Perel, P., Shah, T., Hingorani, A. D., & Casas, J. P. (2011) · JAMA · doi:10.1001/jama.2011.1880 · Cited by 472

Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: An ethnicity-based updated meta-analysis

Jafrin, S., Naznin, N. E., Reza, M. S., Aziz, M. A., & Islam, M. S. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.05.022 · Cited by 17